DDC
Aromatic-L-amino-acid decarboxylase
As of the edition of 20 October 2026, DDC (aromatic-L-amino-acid decarboxylase, UniProt P20711) has 6 drugs tested at it and 10 companies on the list, 3 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P20711
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 8
- Disease areas
- Nervous system; Mental health; Eye; Heart and blood vessels; Inherited and neonatal; Chemically induced; Immune system; Injuries
- Registered trials of its drugs
- 134
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 3 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Carbidopa anhydrous | Marketed | Phase 4 | none listed |
| Benserazide | Marketed | Phase 4 | none listed |
| IPX054 | Went quiet | Phase 2 | none listed |
| ND0612 | Went quiet | Phase 3 | none listed |
| WD-1603 | Went quiet | Phase 1 | none listed |
| Foscarbidopa | Marketed | No phase stated | Ends 2035 |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 3 |
| Engaged | 1 |
| Undetermined | 3 |
| Total on the list | 10 |
The other 7 companies at DDC
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at DDC, ranked, with the facts behind eachRequest access. Nothing is shown until you do.